Mechanism of Action for NNZ-2566 Anti-inflammatory Effects Following PBBI Involves Upregulation of Immunomodulator ATF3
@article{Cartagena2013MechanismOA, title={Mechanism of Action for NNZ-2566 Anti-inflammatory Effects Following PBBI Involves Upregulation of Immunomodulator ATF3}, author={Casandra M Cartagena and Katie L. Phillips and Garry L. Williams and Melissa A. Konopko and Frank C. Tortella and Jitendra R. Dave and Kara E. Schmid}, journal={NeuroMolecular Medicine}, year={2013}, volume={15}, pages={504-514} }
The tripeptide glycine–proline–glutamate analogue NNZ-2566 (Neuren Pharmaceuticals) demonstrates neuroprotective efficacy in models of traumatic brain injury. In penetrating ballistic-like brain injury (PBBI), it significantly decreases injury-induced upregulation of inflammatory cytokines including TNF-α, IFN-γ, and IL-6. However, the mechanism by which NNZ-2566 acts has yet to be determined. The activating transcription factor-3 (ATF3) is known to repress expression of these inflammatory…
22 Citations
The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders
- Biology, MedicineExpert opinion on therapeutic targets
- 2015
These small neuropeptides provide effective neuroprotection by offering an improved pharmacokinetic profile and more practical route of administration compared with IGF-1 administration.
Neuroprotection with Glycine-2-Methylproline-Glutamate (G-2MePE) after hypoxic-ischemic brain injury in adult rats
- Biology, Medicine
- 2014
Neuroprotection with G-2MePE after hypoxic-ischemic brain injury in adult rats is associated with reduced neuronal necrosis, apoptosis, modulated inflammatory responses and augmented astrocytosis.
Microglial Inflammasome Activation in Penetrating Ballistic-Like Brain Injury.
- BiologyJournal of neurotrauma
- 2018
Cell-specific patterns of inflammasome activation and pyroptosis predominantly in microglia are demonstrated, suggesting a sustained pro-inflammatory state following PBBI, thus offering a therapeutic target for this type of brain injury.
Activating transcription factor 3, an early cellular adaptive responder in ischemia/reperfusion-induced injury
- BiologyCi ji yi xue za zhi = Tzu-chi medical journal
- 2018
The role of ATF3 in multiple organs including the kidney, myocardium, and brain following I/R injury is addressed and chronic inflammation-induced pathophysiologies such as diabetes and atherosclerosis are addressed.
Neuroinflammation after Traumatic Brain Injury Is Enhanced in Activating Transcription Factor 3 Mutant Mice.
- BiologyJournal of neurotrauma
- 2018
Activating transcription factor 3 (ATF3), a TF encoding a regeneration-associated gene (RAG) predominantly studied in peripheral nervous system (PNS) injury, is identified as a new TF-mediating TBI-associated CNS inflammatory responses.
The role of microglial inflammasome activation in pyroptotic cell death following penetrating traumatic brain injury
- Biology, MedicineJournal of Neuroinflammation
- 2019
Evidence is provided for inflammasome activation in microglia and infiltrating leukocytes after penetrating traumatic brain injury and a role for pyroptotic cell death in the pathophysiology.
Transcriptional Factors and Protein Biomarkers as Target Therapeutics in Traumatic Spinal Cord and Brain Injury
- BiologyCurrent neuropharmacology
- 2020
Some of the recent transcriptional factors and protein biomarkers that have been developed and discovered in the last decade in the context of targeted therapeutics for SCI and TBI patients are reviewed.
Treatment of traumatic brain injury with anti-inflammatory drugs
- Biology, MedicineExperimental Neurology
- 2016
Pharmacotherapy for Fragile X Syndrome: Progress to Date
- BiologyDrugs
- 2016
A brief summary of the prevalence, phenotypic characteristics, genetic causes and molecular functions of FMRP in the brain, discusses the most recent finding in FXS drug development, and summarizes FXS trials utilizing symptomatic treatment is offered.
Targeted treatments in fragile X syndrome
- Psychology, Biology
- 2014
Although the orphan drugs may improve more generalized symptoms of FXS compared to symptom-based treatments, the most effective treatment response will require a multifaceted approach starting early in life using multiple pharmacological and behavioral interventions.
References
SHOWING 1-10 OF 56 REFERENCES
NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats
- Biology, MedicineJournal of Neuroinflammation
- 2009
The results suggest that the neuroprotective effects of NNZ-2566 may, in part, be functionally attributed to the compound's ability to modulate expression of multiple neuroinflammatory mediators in the injured brain.
NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury.
- Biology, MedicineJournal of neurotrauma
- 2009
It is demonstrated that NNZ-2566 treatment promoted functional recovery following PBBI, an effect related to the modulation of injury-induced neural inflammatory and apoptotic mechanisms.
NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke
- Biology, MedicineJournal of the Neurological Sciences
- 2009
Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro.
- BiologyNeuroreport
- 1999
A neuroprotective role for GPE tripeptide is reported, with enhanced survival of the CA1-2 hippocampal neurons following an excitotoxic insult in vitro, which could lead to new strategies to reduce neuronal death after injury and in disease.
Negative Regulation of TLR-Signaling Pathways by Activating Transcription Factor-31
- Biology, ChemistryThe Journal of Immunology
- 2007
ATF3 behaves as a negative regulatory transcription factor in TLR pathways and, accordingly, deficiency in atf3 alters responses to immunological challenges in vivo, which merits further exploration in diseases such as type I diabetes and cancer.
Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury.
- Biology, MedicineJournal of neurotrauma
- 2001
This study provides the first evidence that astrocytes, without the influence from other cell types, can produce and release cytokines following mechanical and ischemic injury.
Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4
- BiologyNature
- 2006
Cluster analysis of a comprehensive set of transcriptomic data derived from Toll-like receptor-activated macrophages is used to identify a prominent group of genes that appear to be regulated by activating transcription factor 3 (ATF3), a member of the CREB/ATF family of transcription factors.
Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain.
- BiologyJournal of neurotrauma
- 2008
The data suggest that increased microglial Cyp46 activity is part of a system for removal of damaged cell membranes post-injury, by conversion of cholesterol to 24-hydroxycholesterol and by activation of LXR-regulated gene transcription.
Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury.
- BiologyJournal of neurotrauma
- 2008
It is shown that following TBI, secondary injury chiefly involves inflammatory processes and chemokine signaling, which comprise putative targets for pharmaceutical neuroprotection.
T-cell cytokines in injury-induced neural damage and repair
- Biology, MedicineNeuroMolecular Medicine
- 2007
The role of interferon-γ, interleukin (IL)-2,IL-4, IL-6, and IL-10 in autoimmune diseases such as multiple sclerosis, and primarily “non-immune” injury of the central nervous system (CNS), in particular focal ischemia and trauma is reviewed.